Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepagina
  2. Aandelen
  3. Hongkong
  4. Hong Kong Stock Exchange
  5. Hua Medicine (Shanghai) Ltd.
  6. Nieuws
  7. Andere talen
    2552   KYG4644K1022

HUA MEDICINE (SHANGHAI) LTD.

(2552)
  Rapport
Vertraagde tijd Hong Kong Stock Exchange  -  09:08 29-11-2022
3.620 HKD   +11.73%
24/11Hua Medicine kondigt het vertrek aan van Walter Teh-Ming Kwauk, onafhankelijk niet-uitvoerend bestuurder
CI
18/11Hua Medicine Unit koopt 100% belang in Diabetes Onderzoeksbedrijf
MT
10/10China keurt Hua Medicine's aanvraag voor een nieuw medicijn voor type 2 diabetes behandeling goed; aandelen dalen 11%.
MT
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Dagen
:
Uren
:
Minuten
:
Seconden
Nieuws in andere talen op HUA MEDICINE (SHANGHAI) LTD.
24/11Hua Medicine Announces Demise of Walter Teh-Ming Kwauk, an Independent Non-Executive Di..
18/11Hua Medicine Unit Buys 100% Stake in Diabetes Drug Research Company
10/10China OKs Hua Medicine's New Drug Application for Type 2 Diabetes Treatment; Shares sli..
10/10Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is App..
09/10Hua Medicine Announces Approval of NDA of Huatangning, Innovative First-In-Class GKA Po..
25/08Hua Medicine Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
07/06Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Ins..
13/05Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International To..
17/03Hua Medicine Narrows Loss in 2021 as Expenses Fall
17/03Hua Medicine Announces 2021 Annual Results
17/03Transcript : Hua Medicine Ltd., 2021 Earnings Call, Mar 17, 2022
16/03Hua Medicine Ltd. Announces Board Changes
16/03Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
2021Hua Medicine Shanghai : Hits 65.2% Remission Rate for Investigatio..
2021Hua Medicine Shanghai : Researchers Present Key Research Results on Diabetes Remission of ..
2021Hua Medicine Shanghai : and Sinopharm Announced Supply Chain Strategic Cooperation
2021Hua Medicine : Announces 2020 Interim Results
2021Transcript : Hua Medicine Ltd., H1 2021 Earnings Call, Aug 19, 2021
2021Hua Medicine Ltd. Announces Unaudited Consolidated Earnings Results for the Six Months ..
2021Hua Medicine Shanghai : Grants One Million Share Options to Invest..
2021Hua Medicine Shanghai : China Accepts Application of Hua Medicine'..
2021Hua Medicine : Announces Acceptance of a New Drug Application for Dorzagliatin in China - ..
2021Hua Medicine Shanghai : Voluntary announcement - new drug application for dorzagliatin acc..
2021Hua Medicine Shanghai : Form of proxy for the annual general meeting to be held on tuesday..
2021Hua Medicine Shanghai : (i) proposed re-election of retiring directors; (ii) proposed gran..
2021Hua Medicine Shanghai : Environment, Social and Governance Report 2020
2021Hua Medicine Ltd. Reports Consolidated Earnings Results for the Year Ended December 31,..
2021Hua Medicine Shanghai : Grant of share options
2021Hua Medicine Shanghai : Trims 2020 Loss on Lower Expenses
2021Hua Medicine Shanghai : Milestone Development Achieved in Clinical Trials and Commercializ..
2021Hua Medicine Shanghai : Annual results announcement for the year ended december 31, 2020
2021Hua Medicine Ltd. Announces Audited Consolidated Earnings Results for the Year Ended De..
2021Hua Medicine Ltd. Resolves Not to Declare Any Final Dividend for the Year Ended Decembe..
2021Hua Medicine Ltd. Updates on Its Clinical Trails
2021Hua Medicine Ltd. Obtains Drug Manufacturing Permit for Dorzagliatin
2021Hua Medicine Shanghai : Grants 500,000 Share Options
2020Hua Medicine Announces Topline Results from DAWN
2020Hua Medicine Shanghai : Diabetes Drug Completes Phase III Trial
2020Hua Medicine : Successfully Completes Its Registration Phase III Trials; Announces 52-Week..
2020Hua Medicine Announces Additional Analysis Results from Dorzagliatin's 24-Week Metformi..
2020Hua Medicine : Announces the Drug Manufacturing Permit Granted for Dorzagliatin
2020Hua Medicine Ltd.(SEHK:2552) added to S&P Global BMI Index
2020Transcript : Hua Medicine Ltd., H1 2020 Earnings Call, Aug 18, 2020
2020Hua Medicine Shanghai : Bayer and Hua Medicine announce commercialization agreement and st..
2020Hua Medicine Shanghai : Business update on commercialization agreement and strategic partn..
2020Hua Medicine Ltd. Announces Commercialization Agreement and Strategic Partnership for I..
2020Hua Medicine Shanghai : Interim results announcement for the six months ended june 30, 202..
2020Hua Medicine Ltd. Reports Consolidated Earnings Results for the Six Months Ended June 3..
2020Hua Medicine : Announces Positive 24-Week Topline Results of Phase III Metformin Combinati..
2020Hua Medicine Ltd. Announces Pivotal Phase III Registration Trial Evaluating Dorzagliati..
2020Hua Medicine Ltd. Announces Pivotal Phase III Registration Trial Evaluating Dorzagliati..
2020Hua Medicine Announces Audit Committee Changes
2020Hua Medicine : Successfully Completes SEED (HMM0301), Dorzagliatin's Phase III Monotherapy..
2020Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin's Phase III Monotherap..
2020Hua Medicine Completes Seed, Dorzagliatin’s Phase III Monotherapy Trial
2020Hua Medicine : 's Dorzagliatin Demonstrates Improvements in β-Cell Function in Data P..
2020Hua Medicine’s Dorzagliatin Demonstrates Improvements in ß-Cell Function in Data Presen..
2020Hua Medicine : Selected for Inclusion in the MSCI Hong Kong Micro Cap Index
2020Hua Medicine Selected for Inclusion in the MSCI Hong Kong Micro Cap Index
2020Transcript : Hua Medicine Ltd. Presents at UBS Virtual Global Healthcare Conf..
2020Hua Medicine Announces Positive Results of the Combination Study of Dorzagliatin with E..
2020Hua Medicine : Announces Positive Results in the Combination Study of Dorzagliatin with Em..
2020Hua Medicine : Announces Positive Results of the Combination Study of Dorzagliatin with Em..
2020Hua Medicine Ltd. Reports Consolidated Earnings Results for the Year Ended December 31,..
2020Transcript : Hua Medicine Ltd., 2019 Earnings Call, Mar 17, 2020
2020Hua Medicine : Announces 2019 Annual Results
2020Hua Medicine Provides Updates on Phase III Monotherapy Trial for Dorzagliatin
2020Hua Medicine Shanghai Ltd. Reports Earnings Results for the Full Year Ended December 31..
2020Hua Medicine appoints Dr. Fuxing Tang, a former U.S. FDA Officer, as Chief Technology O..
2020Hua Medicine Appoints Fuxing Tang as Chief Technology Officer
2019Hua Medicine Ltd. Announces Management Changes
2019Hua Medicine's Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Gluco..
2019Hua Medicine’s Pivotal Phase III Monotherapy Trial of Dorzagliatin, a Dual-Acting Gluco..
2019Hua Medicine Reports Unaudited Consolidated Earnings Results for the Six Months Ended J..
2019Hua Medicine – Business & Pipeline Update
2019Hua Medicine Provides Business Update on Product Pipeline for Dorzagliatin
2019Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the Unite..
2019Hua Medicine Initiates First Combination Study of Dorzagliatin with SGLT-2 in the Unite..
2019Certain Ordinary Shares of Hua Medicine Ltd. are subject to a Lock-Up Agreement Ending ..
2019Hua Medicine Ltd. Announces Company Secretary and Authorised Representative Changes
2019Hua Medicine Ltd. Reports Audited Consolidated Earnings Results for the Year Ended Dece..
2019Hua Medicine completes patient enrollment for Phase III monotherapy trial of dorzagliat..
2019Hua Medicine Completes Patient Enrollment for Phase III Monotherapy Trial of Dorzagliat..
2019Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor i..
2019Hua Medicine Initiates First Combination Study of Dorzagliatin with A DPP-4 Inhibitor i..
2018China's Junshi Biosciences raises $394 million after pricing IPO at bottom of range - s..
2018Hua Medicine Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months En..
2018Hua Medicine Ltd. has completed an IPO in the amount of HKD 867.37968 million.
2018Hua Medicine Ltd. has filed an IPO in the amount of HKD 972.13568 million.
2018Hua Medicine Ltd. announced that it has received $117.4 million in funding from a group..
2018Hua Medicine Mulls IPO
2018Hua Medicine Mulls Listing
2017Hua Medicine Seeks Financing
2017Hua Medicine Appoints George Lin as EVP and Chief Financial Officer
2016Hua Medicine Announces Successful Phase 2 Monotherapy Trial for New Class of Diabetes D..
2016Hua Medicine Ltd. announced that it has received $50 million in funding from a group of..
2015Hua Medicine Announces Its Third Clinical Trial of Lead Program HMS5552
2015Hua Medicine Files IND in US for its Novel GKA-Based Diabetes Drug
2015Hua Medicine Ltd. announced that it has received $25 million in funding from group of i..
2014Hua Medicine Ltd. announced that it has received $5.5 million in funding
Volgende evenement op HUA MEDICINE (SHANGHAI) LTD.